We found that blocking the cisplatin/KRAS mutation-induced m6A methylation through METTL3 inhibitor substantially enhances the sensitivity of KRAS-mutant NSCLC cells to cisplatin treatment, both in vitro and in vivo. The gene discussed is METTL3; the disease is non-small cell lung carcinoma.